Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2009

View Archived Issues

Inovio Biomedical reports on preclinical studies of universal influenza vaccine

Sanofi-Aventis reports results from third quarter of 2009

TAK-901 has potent antitumor activity in xenograft mouse models of human malignancies

Roche initiates enrollment of cohort 2 in phase IIb trial of RG-7128 in HCV

AMG-900 exhibits potent activity against multidrug-resistant tumors in preclinical studies

Vical completes final patient follow-up visit of phase II TransVax trial in HCT recipients

Cytheris starts NCI/NIH-sponsored phase I/IIa trial of CYT-107 to enhance tumor vaccination

NIH awards grant to RPCI for study of tamoxifen in breast cancer

Clavis and Clovis sign development and commercialization agreement for CP-4126

FDA grants fast track designation to ARCA biopharma's Gencaro in heart failure

Galapagos initiates phase II clinical study of Nanocort for flares in MS

Addex reports preclinical data on ADX-48621 for Parkinson's disease

Novartis receives approval in Switzerland for Celtura pandemic influenza vaccine

Sinovac Biotech's Panflu.1 H1N1 vaccine approved for geriatric population in China

MenACWY-TT vaccine elicits a persistent immune response in adolescents

Non-adjuvanted H5N1 vaccine containing HA is safe and immunogenic in children

Millennium initiates phase I clinical trial of proteasome inhibitor MLN-9708

Ception Therapeutics and Cephalon provide results of phase IIb/III Cinquil trial

JUPITER data shows that rosuvastatin reduces risk of cardiovascular events

ADX-10059 is safe and effective in healthy subjects; evaluation in GERD anticipated

Shire submits MAA to EMEA for velaglucerase alfa for type 1 Gaucher disease

Palau Pharma discloses H4 receptor antagonists for the treatment of pain

Scancell to initiate a phase I/II trial of DNA ImmunoBody vaccine SCIB1 for melanoma

Gilead identifies SCD inhibitors for the treatment of diabetes

Caspase inhibitors disclosed by LG Life Sciences for acute hepatitis therapy

IRM and Novartis present ALK kinase inhibitors for cancer treatment

Novel 5-HT6 receptor antagonists disclosed by Solvay as anxiolytics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...